더바이오 10월 12일 주요뉴스 [https://www.thebionews.net/edit/webzine.html?idxno=660](https://www.thebionews.net/edit/webzine.html?idxno=660) ●韓 바이오기업에 손 내민 濠 멜버른…“연구시설도, 자금 지원도 있습니다” [https://www.thebionews.net/news/articleView.html?idxno=28877](https://www.thebionews.net/news/articleView.html?idxno=28877) ●1200억 시장 ‘릭시아나’ 특허만료에 ‘염변경’ 승부수…약가방어 경쟁력 확보 [https://www.thebionews.net/news/articleView.html?idxno=28884](https://www.thebionews.net/news/articleView.html?idxno=28884) ●‘181만주 전량 증여’ 국제약품 오너 3세 승계 속도…수익성 회복은 ‘시험대’ [https://www.thebionews.net/news/articleView.html?idxno=28882](https://www.thebionews.net/news/articleView.html?idxno=28882) ●셀트리온, 사상 첫 영업익 5000억원 돌파…분기 최대 실적 경신(종합) [https://www.thebionews.net/news/articleView.html?idxno=28900](https://www.thebionews.net/news/articleView.html?idxno=28900) ●박영민 KDDF 단장 “韓 바이오, 글로벌협력 확대…실질적 신약개발 성과 창출” [https://www.thebionews.net/news/articleView.html?idxno=28912](https://www.thebionews.net/news/articleView.html?idxno=28912) ●HLB, 간암 1차 치료제 후보물질 FDA 허가 재신청…신약 승인 ‘재도전’ [https://www.thebionews.net/news/articleView.html?idxno=28901](https://www.thebionews.net/news/articleView.html?idxno=28901) ●동국제약, 44년만 ‘DK센텔리안’ 사명 변경…글로벌 시장 공략 본격화(종합) [https://www.thebionews.net/news/articleView.html?idxno=28924](https://www.thebionews.net/news/articleView.html?idxno=28924) ●글로벌 빅파마 3社 제시한 신약개발 협력 전략, 공동연구·기술도입·초기투자 [https://www.thebionews.net/news/articleView.html?idxno=28920](https://www.thebionews.net/news/articleView.html?idxno=28920) ●올릭스, 황반변성 치료 후보물질 뉴질랜드 2a상 IND 반려…“보완 후 재제출” [https://www.thebionews.net/news/articleView.html?idxno=28931](https://www.thebionews.net/news/articleView.html?idxno=28931) ●테바, 월 1회 조현병 치료제 ‘웰트루자’ 美 승인…투여 후 모니터링 ‘불필요’ [https://www.thebionews.net/news/articleView.html?idxno=28925](https://www.thebionews.net/news/articleView.html?idxno=28925) ●제테마, 닥터레디와 GLP-1 비만치료제 국내 공급 계약…2028년 상업화 목표 [https://www.thebionews.net/news/articleView.html?idxno=28918](https://www.thebionews.net/news/articleView.html?idxno=28918) ●美 바이오헤이븐, 日 오노에 IgG 분해제 亞 권리 이전…최대 1342억원 규모 [https://www.thebionews.net/news/articleView.html?idxno=28881](https://www.thebionews.net/news/articleView.html?idxno=28881) ●HLB그룹, 신약 결실 넘어 넥스트 성장전략 제시…통합 IR Day 개최 [https://www.thebionews.net/news/articleView.html?idxno=28932](https://www.thebionews.net/news/articleView.html?idxno=28932) ●엘앤씨바이오, 美 기업·조직은행과 ‘리투오’ 6000만달러 규모 독점 공급계약 체결 [https://www.thebionews.net/news/articleView.html?idxno=28938](https://www.thebionews.net/news/articleView.html?idxno=28938) ●애스톤사이언스, HER2 위암백신 후보 ‘AST-301’ 美 FDA 패스트트랙 지정 [https://www.thebionews.net/news/articleView.html?idxno=28928](https://www.thebionews.net/news/articleView.html?idxno=28928) ●삼진제약, ‘A-CLOSE’ 연구 성과 공유…항혈소판 치료전략 논의 [https://www.thebionews.net/news/articleView.html?idxno=28927](https://www.thebionews.net/news/articleView.html?idxno=28927) ●“당뇨병 2차 치료제, 우울증 발생 차이 발생…SGLT2군, DPP-4보다 15%↓” [https://www.thebionews.net/news/articleView.html?idxno=28926](https://www.thebionews.net/news/articleView.html?idxno=28926) ●파마리서치 리쥬란코스메틱, 케이팝데몬헌터스 가수 겸 작곡가 ‘이재’와 협업 [https://www.thebionews.net/news/articleView.html?idxno=28917](https://www.thebionews.net/news/articleView.html?idxno=28917) ●일동제약, ‘CPhI 월드와이드 2026’ 참가…글로벌 사업 기회 모색 [https://www.thebionews.net/news/articleView.html?idxno=28923](https://www.thebionews.net/news/articleView.html?idxno=28923) ●[카드뉴스] 더바이오 주간 ‘톱10’ 뉴스(10월 2주차) [https://www.thebionews.net/news/articleView.html?idxno=28866](https://www.thebionews.net/news/articleView.html?idxno=28866) ●Nexel teams up with Japan’s DNP and CMIC Pharma Science to launch iPSC joint venture ‘TriNebula’ [https://www.thebionews.net/news/articleView.html?idxno=28939](https://www.thebionews.net/news/articleView.html?idxno=28939) ●Txinno Bioscience plans H2 2027 Phase 1 clinical trial application for ULK1-degrading PROTAC ‘TXN12923’ [https://www.thebionews.net/news/articleView.html?idxno=28933](https://www.thebionews.net/news/articleView.html?idxno=28933) ●Samsung Bioepis and Teva Pharmaceuticals to develop and commercialize two biosimilars [https://www.thebionews.net/news/articleView.html?idxno=28937](https://www.thebionews.net/news/articleView.html?idxno=28937) ●Pin Therapeutics seeks accelerated approval for ‘PIN-5018’ in adenoid cystic carcinoma, with MGD expansion to follow [https://www.thebionews.net/news/articleView.html?idxno=28935](https://www.thebionews.net/news/articleView.html?idxno=28935) ●QVIS sets up exclusive booth at Europe’s largest ‘WPSC Europe’ as the only Korean company [https://www.thebionews.net/news/articleView.html?idxno=28934](https://www.thebionews.net/news/articleView.html?idxno=28934) ●Dt&CRO bolsters competitiveness as a full-cycle new drug development CRO, widens academia and industry collaboration [https://www.thebionews.net/news/articleView.html?idxno=28930](https://www.thebionews.net/news/articleView.html?idxno=28930) ●GC Chairman Huh Il-sup: “Productivity must be reinvented through AI and data use” [https://www.thebionews.net/news/articleView.html?idxno=28929](https://www.thebionews.net/news/articleView.html?idxno=28929) *제약바이오 10월 12일 아침 유튜브 라디오 뉴스(매일 아침 업로드) [https://www.youtube.com/watch?v=LxWYn1XtvxQ](https://www.youtube.com/watch?v=LxWYn1XtvxQ)